Shanghai Henlius Biotech, Inc.

HK$49.02As of Sun 8 Nov 2026, 12:00 UTC
HKEX:2696Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 7Y CAGR 0.12%
Div yield —
ROE 21.83%
Biotechnology
Beta (5Y) 0.63
PE TTM 26.88
TSR TTM (29.82%)
Mkt cap HK$26.73B
ROIC 11.17%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$51
4.60%
(78.94%)
Hold 10|0|11|5|12
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.86
0.96
1.01
1.10
(1.55%)
13.27%
18.73%
27.60%
Revenue¥B
1.440
1.457
1.418
1.424
9.58%
10.64%
3.44%
(0.38%)
Peers (US$3.409B)
Cap (US$)
PE
3.756B
35.19x
3.366B
38.24x
Capital
TTM
5Y
10Y
Leveragex
2.109
(0.056)
(0.041)
EBIT/Intx
0.735
0.267
0.193
Own earn%
(73.59)
3.54
15.57
Sh yield%
50.31
13.76
15.16
Owners
Insiders/Inst%
0.80
34.31
Short interest%
5.83
SBC / revenue%
5.74
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
13–23
$1 testx
—
Incr. ROIC%
25